Cullinan Oncology Inc
NASDAQ:CGEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xvivo Perfusion AB
STO:XVIVO
|
SE |
|
S
|
Shagrir Group Vehicle Services Ltd
TASE:SHGR
|
IL |
|
Edesa Biotech Inc
NASDAQ:EDSA
|
CA |
|
L
|
Leader Environmental Technologies Ltd
SGX:LS9
|
SG |
|
B
|
Boombit SA
WSE:BBT
|
PL |
|
N
|
Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
|
TW |
|
TechnologyOne Ltd
ASX:TNE
|
AU |
|
MINISO Group Holding Ltd
NYSE:MNSO
|
CN |
|
E
|
Engcon AB
STO:ENGCON B
|
SE |
|
Yamaichi Electronics Co Ltd
TSE:6941
|
JP |
|
D
|
Deutsche Telekom AG
OTC:DTEGY
|
DE |
|
Synnex Technology International Corp
TWSE:2347
|
TW |
|
B
|
Bank of Ireland Group PLC
ISEQ:BIRG
|
IE |
|
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
|
BR |
|
Regional Management Corp
NYSE:RM
|
US |
|
S
|
SMI Vantage Ltd
SGX:Y45
|
SG |
|
GRM Overseas Ltd
NSE:GRMOVER
|
IN |
|
Shalimar Paints Ltd
NSE:SHALPAINTS
|
IN |
|
3M Co
NYSE:MMM
|
US |
|
S
|
SG Corp
KRX:004060
|
KR |
|
Tata Metaliks Ltd
NSE:TATAMETALI
|
IN |
|
C
|
CX Technology Corp
TWSE:2415
|
TW |
|
O
|
Outin Futures Co Ltd
KOSDAQ:227610
|
KR |
|
Fulgent Sun International (Holding) Co Ltd
TWSE:9802
|
TW |
Cullinan Oncology Inc
Research & Development
Cullinan Oncology Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cullinan Oncology Inc
NASDAQ:CGEM
|
Research & Development
-$142.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Cullinan Oncology Inc
Glance View
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
See Also
What is Cullinan Oncology Inc's Research & Development?
Research & Development
-142.9m
USD
Based on the financial report for Dec 31, 2024, Cullinan Oncology Inc's Research & Development amounts to -142.9m USD.
What is Cullinan Oncology Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-53%
Over the last year, the Research & Development growth was 4%. The average annual Research & Development growth rates for Cullinan Oncology Inc have been -35% over the past three years , -53% over the past five years .
